Table II.
Clinical features of included cases.
| Characteristics (n=95) | Measure, n (% total) |
|---|---|
| Patient age, mean, median (range), years | 53.3, 54 (11–80) |
| Male, mean (n=65) | 54.9 |
| Female, mean (n=30) | 50 |
| Symptoms (n=67) | |
| Hoarseness | 46 (69) |
| Dysphonia | 7 (10) |
| Dyspnea | 13 (19) |
| Dysphagia | 9 (13) |
| Stridor | 6 (9) |
| Cough | 6 (9) |
| Sore throat | 3 (4) |
| Hemoptysis | 3 (4) |
| Laryngeal foreign body sensation | 3 (4) |
| Laterality (n=41) | |
| Right | 19 (46) |
| Left | 17 (41) |
| Both | 5 (12) |
| Primary site (n=79) | |
| Glottis | 19 (24) |
| Supraglottis | 41 (52) |
| Epiglottis | 12 (15) |
| Aryepiglottic fold | 4 (5) |
| Arytenoid | 3 (4) |
| False vocal cord | 8 (10) |
| Multiple sites | 2 (3) |
| Unknown detailed site | 12 (15) |
| Subglottis | 10 (13) |
| Hemilarynx or 2–3 parts of the larynx | 9 (11) |
| Cervical lymph nodes involvement (n=12) | |
| Glottic patient | 1 (8) |
| Supraglottic patient | 8 (67) |
| Hemilaryngeal patient | 1 (8) |
| Coexistence with other body sites involved | 17 |
| Treatment (n=96) | |
| Radiotherapy alone | 41 (43) |
| Surgery alone | 21 (22) |
| Chemotherapy alone | 1 (1) |
| Surgery and radiotherapy | 28 (29) |
| Radiotherapy and chemotherapy | 3 (3) |
| Surgery and chemotherapy | 1 (1) |
| Radiotherapy, surgery, and chemotherapy | 1 (1) |
| Radiotherapy dose, mean, median (range), Gy | 49.6, 50 (30–70) |
| No treatment (n=3) | |
| Follow-up, mean, median (range), ms (n=90) | 60, 45 (1.5–300) |
| Recurrence or metastasis | 21 (23) |
| No recurrence or metastasis | 69 (77) |
| MM | 6 (7) |
| AML | 1 (1) |
| Outcome (n=91) | |
| ANED | 63 (69) |
| AWD | 13 (14) |
| DOD | 6 (7) |
| DOC | 9 (10) |
ms, months; MM, multiple myeloma; AML, acute myeloid leukaemia; ANED, alive, no evidence of disease; AWD, alive with disease; DOD, died of disease; DOC, died of other causes.